原发灶不明的转移癌合并副肿瘤性皮肌炎1例并文献复习
A Case Report and Literature Review of Metastatic Carcinoma of Unknown Primary Complicated with Paraneoplastic Dermatomyositis
摘要: 目的:通过报告1例原发灶不明的转移癌合并副肿瘤性皮肌炎的诊疗过程,并复习相关文献,为此类患者的诊疗提供参考。方法:回顾性分析1例青壮年原发灶不明的颈部淋巴结转移癌合并副肿瘤性皮肌炎的诊疗过程及诊疗依据,并复习相关文献。结果:通过规范诊疗及多学科协作,制定了个体化的高效低毒治疗方案,使患者获得了长达8年的生存期和良好的生活质量。结论:青壮年皮肌炎患者亦需注意肿瘤的排查,副肿瘤性皮肌炎的治疗需遵循“肿瘤治疗优先”原则,肿瘤根治后皮肌炎症状可显著缓解。原发灶不明的颈部淋巴结转移癌需进行全面的影像学、血清学及病理学检查积极查找原发灶,原发灶不明确的可根据病理类型选择广谱的抗肿瘤药物治疗,积极处理并发症有助于改善生存时间及生活质量。
Abstract: Objective: To report the diagnosis and treatment of a case of metastatic carcinoma of unknown primary complicated with paraneoplastic dermatomyositis, and to review the relevant literature, so as to provide a reference for the diagnosis and treatment of such patients. Methods: The diagnosis, treatment and relevant evidence of a young and middle-aged patient with cervical lymph node metastatic carcinoma of unknown primary combined with paraneoplastic dermatomyositis were retrospectively analyzed, and the related literature was reviewed. Results: Through standardized diagnosis and treatment as well as multidisciplinary collaboration, an individualized high-efficiency and low-toxicity therapeutic regimen was formulated, enabling the patient to achieve an 8-year survival period and a good quality of life. Conclusion: Tumor screening should also be considered in young and middle-aged patients with dermatomyositis. The treatment of paraneoplastic dermatomyositis should follow the principle of “priority of tumor treatment”. Dermatomyositis symptoms can be significantly relieved after radical tumor resection. Patients with cervical lymph node metastatic carcinoma of unknown primary require comprehensive imaging, serological and pathological examinations to actively identify the primary lesion. If the primary lesion remains unidentified, broad-spectrum antitumor drugs can be selected according to the pathological type. Active management of complications helps improve survival time and quality of life.
文章引用:付文倩, 韩梦琳, 王琪, 王海冀, 郭天慧, 高文, 张碧媛. 原发灶不明的转移癌合并副肿瘤性皮肌炎1例并文献复习[J]. 临床医学进展, 2026, 16(3): 3737-3744. https://doi.org/10.12677/acm.2026.1631181

参考文献

[1] Iaccarino, L., Ghirardello, A., Bettio, S., Zen, M., Gatto, M., Punzi, L., et al. (2014) The Clinical Features, Diagnosis and Classification of Dermatomyositis. Journal of Autoimmunity, 48, 122-127. [Google Scholar] [CrossRef] [PubMed]
[2] Gerami, P., Schope, J.M., McDonald, L., Walling, H.W. and Sontheimer, R.D. (2006) A Systematic Review of Adult-Onset Clinically Amyopathic Dermatomyositis (Dermatomyositis Siné Myositis): A Missing Link within the Spectrum of the Idiopathic Inflammatory Myopathies. Journal of the American Academy of Dermatology, 54, 597-613. [Google Scholar] [CrossRef] [PubMed]
[3] Khanna, U., Galimberti, F., Li, Y. and Fernandez, A.P. (2021) Dermatomyositis and Malignancy: Should All Patients with Dermatomyositis Undergo Malignancy Screening? Annals of Translational Medicine, 9, 432-432. [Google Scholar] [CrossRef] [PubMed]
[4] Chen, D., Yuan, S., Wu, X., et al. (2014) Incidence and Predictive Factors for Malignancies with Dermatomyositis: A Cohort from Southern China. Clinical and Experimental Rheumatology, 32, 615-621.
[5] Didona, D., Fania, L., Didona, B., Eming, R., Hertl, M. and Di Zenzo, G. (2020) Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis. International Journal of Molecular Sciences, 21, Article 2178. [Google Scholar] [CrossRef] [PubMed]
[6] Qiang, J.K., Kim, W.B., Baibergenova, A. and Alhusayen, R. (2016) Risk of Malignancy in Dermatomyositis and Polymyositis. Journal of Cutaneous Medicine and Surgery, 21, 131-136. [Google Scholar] [CrossRef] [PubMed]
[7] Silva, J.A.D., Mesquita, K.D.C., Igreja, A.C.D.S.M., Lucas, I.C.R.N., Freitas, A.F., Oliveira, S.M.D., et al. (2013) Paraneoplastic Cutaneous Manifestations: Concepts and Updates. Anais Brasileiros de Dermatologia, 88, 9-22. [Google Scholar] [CrossRef] [PubMed]
[8] Cristofori, M., González-Rodríguez, J.C., Cortés-Marín, E.E., Sallón, A. and Sandoval, J. (2025) Dermatomyositis: A Narrative Review of Skin as a Window to Muscle and Malignancy. Cureus, 17, e88601. [Google Scholar] [CrossRef] [PubMed]
[9] Didona, D., Rallo, A., Carugno, A. and Paolino, G. (2025) Paraneoplastic Dermatoses: A Clue for Underlying Malignancies. Journal of Clinical Medicine, 14, Article 1014. [Google Scholar] [CrossRef] [PubMed]
[10] Zhou, S. and Chen, X. (2015) Inflammation, Cytokines, the Il-17/IL-6/STAT3/NF-κB Axis, and Tumorigenesis. Drug Design, Development and Therapy, 9, 2941-2946. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, X., Li, B., Lan, T., Chiari, C., Ye, X., Wang, K., et al. (2025) The Role of Interleukin-17 in Inflammation-Related Cancers. Frontiers in Immunology, 15, Article ID: 1479505. [Google Scholar] [CrossRef] [PubMed]
[12] Balboni, I., Niewold, T.B., Morgan, G., Limb, C., Eloranta, M., Rönnblom, L., et al. (2013) Brief Report: Interferon‐α Induction and Detection of Anti‐Ro, Anti‐La, Anti‐Sm, and Anti‐RNP Autoantibodies by Autoantigen Microarray Analysis in Juvenile Dermatomyositis. Arthritis & Rheumatism, 65, 2424-2429. [Google Scholar] [CrossRef] [PubMed]
[13] Huard, C., Gullà, S.V., Bennett, D.V., Coyle, A.J., Vleugels, R.A. and Greenberg, S.A. (2017) Correlation of Cutaneous Disease Activity with Type 1 Interferon Gene Signature and Interferon Β in Dermatomyositis. British Journal of Dermatology, 176, 1224-1230. [Google Scholar] [CrossRef] [PubMed]
[14] Darnell, J.E., Kerr, L.M. and Stark, G.R. (1994) Jak-Stat Pathways and Transcriptional Activation in Response to IFNS and Other Extracellular Signaling Proteins. Science, 264, 1415-1421. [Google Scholar] [CrossRef] [PubMed]
[15] Leclair, V., Galindo-Feria, A.S., Rothwell, S., et al. (2023) Distinct HLA Associations with Autoantibody-Defined Subgroups in Idiopathic Inflammatory Myopathies. EBioMedicine, 96, Article 104804.
[16] Schiller, M., Böhm, M., Hensen, P., Riemann, H., Luger, T.A. and Nashan, D. (2006) Dermatomyositis Associated with Malignant Melanoma—A Marker of Poor Prognosis? Journal of the American Academy of Dermatology, 54, 221-226. [Google Scholar] [CrossRef] [PubMed]